[Multicomponent vaccine VP-4 in the therapy of XXXX ].

@entity1 @entity404 @entity565 @entity2144 @entity56 @entity42428
In the present study the results of the polycomponent vaccine B[symbol: see text]-4 use for the therapy of @entity1 with @entity565 ( @entity565 ) and @entity2144 were generalized. The vaccine was introduced by the nasal-subcutaneous or nasal-oral administration simultaneously with the basic therapy. Te studies were conducted first on limited groups of @entity1 , then in the course of the State Trial with the use of placebo control. Excellent and good effect lasting for 1 year and over was registered in 36 @entity1 (66.7%) out of 54 @entity565 @entity1 receiving the vaccine by the intranasal-subcutaneous method. Immunotherapy produced no positive effect in 13 @entity1 (24.1%). Out of 35 examined @entity1 receiving the vaccine by the intranasal oral method, excellent and good effect was registered in 26 @entity1 (74.2%). No effect was registered in 4 @entity1 (11.4%). In the group of 28 @entity1 receiving placebo simultaneously with the basic therapy positive dynamics in the course of the disease was observed only in 3 @entity1 . Treatment with polycomponent vaccine B[symbol: see text]-4 led to a prolonged (to a year and more) decrease in the frequency and severity of exacerbations, contributed to the prolongation of remissions and to a decrease in the amount of administered medicinal preparations, especially systemic corticosteroids. Immunotherapy ensured the correction of the content of lymphocyte subpopulations with markers CD3, @entity404 , @entity42428 and a rise in the titers of antibodies to antigens contained in the preparation. The use of therapeutic polycomponent vaccine B[symbol: see text]-4 for the treatment of @entity1 with @entity2144 ensured the state of prolonged remission in this group of @entity1 . On the basis of our investigations we believe that the use of the therapeutic polycomponent vaccine B[symbol: see text]-4 may be included into the basis therapy of @entity56 .
